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Abstract
Rationale: X-linked adrenoleukodystrophy (X-ALD) is a rare disorder caused by mutations in the ABCD1 gene, coding for
peroxisomal membrane transporter adrenoleukodystrophy (ALD) protein. The disease is characterized by accumulation of very long
chain fatty acids (VLCFAs) in tissues. Adult adrenomyeloneuropathy (AMN) and the cerebral inflammatory form of ALD are the main
phenotypes presenting various symptoms.
Patient concerns: We report a case of 37-year-old patient with diagnosis of X-ALD, confirmed based on elevated VLCFA
concentrations and genetic testing of ABCD1 gene. The complete clinical picture in the patient indicates AMN phenotype with
cerebral involvement.
Diagnoses: The reduced synthesis of unconjugated cholic and chenodeoxycholic acids, and the reduction to 28% to 29% of
peroxisomal beta-oxidation of behenic acid and normal peroxisomal metabolism of pristanic and palmitic acid were observed in the
X-ALD patient. Sanger sequencing of major genes involved in primary bile acid (BA) synthesis failed to identify pathogenic mutations
of the investigated set of genes.
Interventions: Plasma concentrations of BAs, VLCFAs, and beta-oxidation of C22:0, C16:0, and pristanic acid were studied in
primary skin fibroblasts of the patient. In addition, we performed sequencing of the ABCD1, ABCD3, CYP7A1, CYP7B1, CYP27A1,
HSD3B7, AKR1D1, and SLC27A5 genes in the X-ALD family.
Outcomes: In the Polish family affected with AMN a dysregulation of the primary BA synthesis pathway was found.
Lessons:We have demonstrated the coincidence of the adult form of X-ALD with abnormalities in BA synthesis. We suggest that
decreased synthesis of BAs may be an additional dysfunction as a consequence of the ABCD1 c.659T>C, p.(Leu220Pro) mutation
and may be further evidence that disturbed cholesterol metabolism is important in the pathology of ALD.
Abbreviations: 7KC = 7-ketocholesterol, ALD = adrenoleukodystrophy, ALDP = ALD-protein, AMN = adrenomyeloneuropathy,
BA = bile acid, CA = cholic acid, CALD = cerebral inflammatory form of adrenoleukodystrophy, CDCA = chenodeoxycholic acid,
DHCA= 3a,7a-dihydroxycholestanoic acid, LGMD = Laboratory Genetic Metabolic Diseases, PI (4,5)P2= phosphatidylinositol-4,5-
bisphosphate, PMP70 = peroxisomal membrane protein 70, THCA = 3a,7a,12a-trihydroxycholestanoic acid, VLCFA = very long
chain fatty acid, X-ALD = X-linked adrenoleukodystrophy.
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1. Introduction
X-linked adrenoleukodystrophy (X-ALD, OMIM 300100) is a
rare genetic neurodegenerative disease with recessive inheritance,
linked to the X chromosome. X-ALD is characterized by the
accumulation of saturated, unbranched very long chain fatty
acids (VLCFAs) with more than 22 carbon atoms (VLCFA) in
blood and tissues. A known cause of the disease is mutations in
theABCD1 gene encoding the ALD-protein (ALDP) transporting
VLCFA into peroxisomes for degradation by the enzymes of the
beta-oxidation pathway. Twomain phenotypes are known: adult
adrenomyeloneuropathy (AMN) and the cerebral inflammatory
form of adrenoleukodystrophy (CALD).[1] AMN occurs in men
and with disease manifestation appearing between the ages of 20
and 40. AMN is characterized by a noninflammatory, slowly
progressive neuropathy within the spinal cord and peripheral
nerves.[2] The main symptoms include spastic paraparesis,
sensory disturbances, and overactive bladder. Some patients
with AMN have adrenal insufficiency.[2] The second phenotype
CALD with inflammatory involvement is very severe, together
with rapidly progressive decline in cognitive function and
neurological disorders. The immune response in CALD and
AMN varies and induction of the pathology may depend on
different lipid classes. The incidence of X-ALD is estimated to be
about 1:17 000 live births, which is considered the most common
peroxisomal disease and inherited disease of the white matter of
the central nervous system.[3] Within 1 family different forms of
the disease with various levels of severity can occur, without any
link between genotype and X-ALD phenotype, which suggests
involvement of other mechanisms including environmental
factors. Moreover, monozygotic twins were reported to demon-
strate differing phenotypes.[4] Many studies have been done to
search for phenotype modifying genes in ALD. Genes associated
with fatty acid metabolism (ABCD2, ABCD3, and ABCD4),
inflammation (TNFalpha, MOG, CD1, IL6, HLA, and SOD2),
and vitamin B12 metabolism (ABCD4, TCN2, DHFR, CBS,
MTR, MTHFR, MTRR, and RCFI) were studied.[5] Because of
the lack of correlation between mutations in the ABCD1 gene
and phenotype it seems to be appropriate to search for other
mechanisms involved in the clinical course of the disease, the
pathways and processes that may be disrupted, coexisting
mutations in other genes related to lipid metabolism and
peroxisomes or epigenetic regulations. Here, we present a
clinical case study evaluating VLCFAs and bile acids (BAs)
metabolism disorders in a Polish family with X-ALD.
2. Methods
2.1. Ethical approval and consent to participate
The study, sample collection, and all procedures were approved
by the Ethical Committee of the Jagiellonian University, Krakow,
Poland number KBET/95/B/2012. Individual written informed
consents to participate in the study were obtained from patients.
2.2. Consent to publication
Written informed consents to publication were obtained from
patients.
2.3. Sample collection
Analyses of plasma BAs levels and sequencing of genes related to
ALDP and peroxisomal membrane protein 70 (PMP70) trans-
porters and genes from primary BA synthesis pathway were
performed in the patient with suspicion of ALD (named X-ALD
patient 1), as well as his mother and brother. The control group
included 2 healthy subjects matched for age and sex. In addition
screening of peroxisomes was performed on fibroblasts taken
from the X-ALD patient 1. Gene expression analysis was made
on fibroblasts collected from X-ALD patient 1 and a fibroblasts
from a second ALD patient hemizygous to c.1661G>A, p.
(Arg554His) mutation (named X-ALD 2) and 2 healthy men.
Samples of peripheral blood were collected from the X-ALD
patient 1, his available family members, and the control patients to
perform genetic testing and lipid screening analysis. Skin biopsies
were taken from the forearm to conduct fibroblast cultures.
2.4. Studies in plasma and on DNA isolated from whole
blood cells
2.4.1. Quantification of human BAs in plasma by High-
performance liquid chromatography mass spectrometry.
Ethylenediamine tetra-acetic acid plasma was separated from
peripheral blood samples and frozen at 80°C and subsequently
sent to the Institute for Clinical Chemistry and Laboratory
Medicine University Hospital in the laboratory of Prof Gerd
Schmitz in Regensburg (Germany) to determine BAs and sterol
concentration. BA species were quantified by liquid chromatog-
raphy-tandem mass spectrometry (LC-MS/MS) as described
previously.[6,7] Briefly, plasma samples were spiked with a
mixture of deuterated BAs as internal standard before protein
precipitation. Plasma extracts were subjected to LC-MS/MS
detection in negative ion mode after baseline separation of
isobaric species. The LC-MS/MS system consisted of an API 4000
QTrap (AB Sciex, Darmstadt, Germany) that was coupled with
electrospray ionization. Chromatographic separation was
achieved by the Agilent 1200HPLC system (Agilent, Waldbronn,
Germany). Quantification was achieved using a matrix calibrator
generated by standard addition.
2.4.2. Sanger sequencing.DNAwas extracted from peripheral
blood. Polymerase chain reaction (PCR) amplification of coding
regions and intron/exon boundaries of the peroxisomal trans-
porter ABCD1 and ABCD3 genes and CYP7A1, CYP7B1,
CYP27A1, HSD3B7, AKR1D1, and SLC27A5 genes from
primary BAs pathway were carried out using standard protocols.
Lists of PCR primers and amplification protocols used for
sequencing are added as supplementary files, http://links.lww.
com/MD/C648. Sanger amplification was performed using
BigDye Terminator cycle sequencing chemistry and separated
using the ABI3130XL capillary sequencer. Sequence data were
compared to the appropriate reference sequences from the
ENSEMBL database according to Human Genome Variation
Society guidelines.
2.5. Studies in fibroblasts
Human skin fibroblasts derived from X-ALD patient 1 and X-
ALD patient 2 and from the 2 control subjects were cultured in
Dulbecco’s Modified Eagle’s Medium containing 10% fetal
bovine serum and 1% antibiotic and grown at 37°C at 5% CO2
concentration.
2.5.1. VLCFAs level in fibroblasts of X-ALD patient 1. VLCFA
levels were measured in fibroblasts at the Laboratory Genetic
Metabolic Diseases (LGMD) in the Academic Medical Center in
Amsterdam using electrospray ionization mass spectrometry as
described previously by Valianpour et al.
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2.5.2. Peroxisomal screening and analysis of beta-oxidation
in fibroblasts of X-ALD patient 1. Peroxisomal screening
included immunofluorescence microscopy measurement of the
amount of catalase, detection of the ALDP and PMP70 using
antibodies raised against catalase, ALD protein, and PMP70
according to the procedure described by Wanders et al.[8,9] In
addition peroxisomal beta-oxidation was studied using radio-
labeled C22:0, C16:0, and pristanic acid to assess peroxisomal
metabolism in 2 independent experiments and compared to
laboratory reference values as described.[10,11] All analyses were
performed at the LGMD in the Academic Medical Center in
Amsterdam.
2.6. Gene expression
Total RNA was isolated from the cultured fibroblasts
using the RiboPure Kit (Ambion). Samples with RIN
above 8.0 were selected for further analysis. Sample
preparations for Agilent microarray hybridization (SurePrint
G3 Unrestricted Human GE 8x 60K Microarray -AMADID-
G4858A_028004) were performed according to the manufac-
turer’s instruction.
Data analysis was performed based on the limma[12] library in
R environment [R Core Team (2016)]. Normalization and data
analysis were performed for 1-color spottedmicroarrays. A linear
model was used for analyzing designed experiments and the
assessment of differential expression by comparison of selected
groups of data X-ALD versus control patients. A linear model
(lmFit and contrasts.fit functions) was used to compute fold
changes and t-statistics for the contrasts of interest. Adjustment
for multiple testing, using Benjamini and Hochberg method to
control the false discovery rate at 5% across all genes and all
contrasts was calculated.
3. Case report
3.1. Case description of the X-ALD patient
A 37-year-old man presented with a 7-year history of progressive
behavioral abnormality, difficulty in walking due to axonal and
demyelination injury, and disorder of micturition with distur-
bances of the storage function of the bladder. His medical history
includes information about thinning eyebrows and hair starting
at the age of 4 years. The patient experienced his first epileptic
attack at the age of 37 years, with subsequent reoccurrence.
Endocrine testing showed high level of serum adrenocorticotro-
pic hormone, lack of adrenal reserve in the short Synacthen test,
and low level of dehydroepiandrosterone sulfate allowing the
suspicion of ALD. Magnetic resonance imaging of the brain
showed abnormal signal intensities in the white matter typical for
ALD, with increased signal on T2 and decreased signal on the T1
sequence located in the parieto-occipital and corpus callosum.
Electromyography showed axonal and demyelinating injury in
the right peroneal nerve. The diagnosis of X-ALD was confirmed
based on elevated VLCFA concentrations and genetic testing of
ABCD1 gene. The complete clinical picture in the patient
indicates AMN phenotype with cerebral involvement. The
parameters such as aminotransferases and bilirubin levels were
within normal limits, whereas liver ultrasonography showed no
abnormalities.
Family history revealed that the patient’s mother, father, and
younger brother were ALD asymptomatic. Carrier testing
documented the ABCD1 mutation in the mother.
3.2. ABCD1 mutation analysis
ABCD1 gene sequencing revealed a hemizygous c.659T>C, p.
(Leu220Pro) mutation in exon 1 in peripheral blood DNA of the
X-ALD patient 1. Carrier testing revealed the presence of the
same heterozygous ABCD1 mutation in the mother. At DNA
of X-ALD 2 patient was detected as hemizygous c.1661G>A,
p.(Arg554His) mutation in 7 exon ofABCD1 gene. The results of
sequencing of the gene ABCD1 in X-ALD patient 1 and family is
shown in Figure 1.
3.3. Determination of VLCFA concentrations and
beta-oxidation activity of C22:0 and C16:0 fatty acid
in X-ALD patient 1 fibroblasts
X-ALD patient 1 had an abnormal VLCFAs profile with
increased C26:0 concentration and C24:0/C22:0 and C26:0/
C22:0 ratio (Table 1). The peroxisomal beta-oxidation activity of
the C22:0 was reduced to 28% to 29% as shown by a reduced
C16:0/C22:0 ratio in 2 independent experiments compared to
laboratory reference values (Table 1).
3.4. Analysis of plasma bile acids and sterols
We found a significant decrease in plasma BAs levels in the X-
ALD patient 1 as shown in Table 2. In general, total plasma BAs
and the primary BA species were significantly lower compared to
the healthy controls. Among all species-free BA species revealed
the most significantly reduced plasma levels, with very low levels
of unconjugated cholic acid (CA) and chenodeoxycholic acid
(CDCA). The level of BAs was more reduced in the patient’s
mother. In addition, analysis of the sterol levels in the plasma
showed a significant reduction of lathosterol in the X-ALD
patient 1 relative to control subjects (Fig. 2).
3.5. Beta-oxidation with pristanic acid as substrates
in X-ALD patient 1 fibroblasts
We found a normal beta-oxidation of pristanic acid in
peroxisomes of fibroblasts from X-ALD patient 1 (Table 1).
Pristanic acid was used as a representative marker of proper beta-
oxidation of branched chain fatty acids because BAs intermediate
are handled by the same enzymes: alpha-methylacyl-CoA
racemase, acyl-CoA oxidase 2, hydroxysteroid 17-beta dehydro-
genase 4, and sterol carrier protein 2.
3.6. Sequencing of genes ABCD3, CYP7A1, CYP7B1,
CYP27A1, HSD3B7, AKR1D1, and SLC27A5
No genetic mutations were found with high probability to affect
function of constituents of the pathway analyzed potentially
causing an abnormal BA profile (Table 3).
3.7. Gene expression in fibroblasts of AMN patients
Gene expression analysis was performed on Agilent microarrays
(see methods for detail) to search for genes and related pathways
involved in the pathogenesis of the disease, related especially to
peroxisomes and cholesterol synthesis. We demonstrated a
statistically significant 4.4-fold decrease in expression of the
pleckstrin homology domain containing A6 (PLEKHA6) gene
and 5.7-fold increase of LXN (latexin) gene (adj.P< .05) in X-
ALD versus control patients. The third gene, lysosomal protein
transmembrane 5 (LAPTM5) (fold of change [FC]=5.1
Płatek et al. Medicine (2018) 97:49 www.md-journal.com
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Figure 1. The electropherograms of exon 1 sequencing in ABCD1 gene in family members showing position 659 of the coding DNA sequence. X-ALD=X-linked
adrenoleukodystrophy.
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upregulated) showed a moderate trend toward significance (adj.
P= .062), which may also suggest the involvement of this protein
in the pathogenesis of X-ALD; results presented in Table 4).
4. Discussion
In our patient (X-ALD 1) we detected a previously described
homozygous c.659T>C, p.(Leu220Pro) mutation in the ABCD1
gene.[13] Analysis of the VLCFAs level and beta-oxidation of
C22:0 in the patient’s fibroblasts confirmed the diagnosis of the
X-ALD in the patient.[14]
Furthermore, for the first time we have demonstrated the
coincidence of the adult form of X-ALDwith abnormalities in BA
synthesis. The reduced synthesis of primary BAs especially CA
and CDCAwas observed in the X-ALD patient 1 and his mother.
There are many descriptions of clinical cases related to
disorders in peroxisome metabolism; however, there are no
reports on simultaneous increase in VLCFAs and reduction of CA
and CDCA. Patients with Zellweger syndrome have a decreased
number of hepatic peroxisomes, impaired plasmalogen synthesis,
and increased levels of VLCFA, BAs precursors, pipecolic and
phytanic acids.[15] This group described 19 adult Zellweger
syndrome patients, presenting a wide range of symptoms, but
none of them had both CA and CDCA levels below reference
value and at the same time increased C26:0 levels.[15] The used in
our study catalase immunofluorescence method documented
presence of the not impaired catalase importing peroxisomes in
patient fibroblasts. In addition, the absence symptoms of hepatic
injury exclude peroxisomal biogenesis disorder.
The abnormal BA profile suggests that the disorder could be a
result of a coexistence of a mutation in another gene, probably
influencing the metabolism of BAs. X-linked ALD is a
peroxisomal disorder and BAs are metabolized in peroxisomes;
therefore, we suspected disturbances in these organelles. Normal
beta-oxidation of branched chain fatty acids was observed in the
X-ALD patient 1 fibroblasts, suggesting that BAs beta-oxidation
inside the peroxisome was not disturbed. The BA profile suggests
that there may be either an impaired transport of 3a,7a-
dihydroxycholestanoic acid (DHCA) and 3a,7a,12a-trihydrox-
ycholestanoic acid (THCA) into the peroxisomes due to lack of
acyl-CoA synthetase producing DHCA-CoA and THCA-CoA or
absence of its transporter. It has been demonstrated that the
transport of DHCA-CoA and THCA-CoA into peroxisomes is
mediated by the PMP70 protein encoded by theABCD3 gene.[11]
Therefore we checked for the presence of the PMP70 protein in
the peroxisomal membrane by microscopy with antibodies
against this protein, which revealed normal peroxisomal staining.
Sanger sequencing of the ABCD3 gene demonstrated no
mutation. Furthermore we excluded mutations in the patient’s
main genes related to the synthesis of BAs outside the
Table 2
Plasma bile acids in the family members.
Bile acids
X-ALD
proband
Mother of
X-ALD proband
Brother of X-ALD proband/
without ABCD1 gene mutation
Control
subject 1
Control
subject 2
Reference
values, nmol/L
Sum of all bile acids classes 800 300 1900 1600 2400 1500–6000
Primary bile acids 500 100 1600 900 1300 700–4200
Secondary bile acids 300 200 300 700 1100 400–3800
Free bile acids 80 110 190 860 1000 250–2800
Conjugated bile acids 720 190 1710 740 1400 760–7200
Bile acid species:
Cholic acid (CA) 11 <6 <6 77 119 50–700
Glycocholic acid (GCA) 95 23 371 91 250 60–900
Taurocholic acid (TCA) 23 <5 33 <5 16 <200
Chenodeoxycholic acid (CDCA) <2 <2 121 350 199 40–1200
Glyco-CDCA (GCDCA) 285 36 996 278 589 300–3000
Tauro-CDCA (TCDCA) 99 64 125 78 101 10–800
X-ALD=X-linked adrenoleukodystrophy.
Table 1
Results of very long chain fatty acid levels and activity of beta-oxidation with C22:0, C16:0, and pristanic acids as substrates in fibroblasts
of X-linked adrenoleukodystrophy patient 1.
VLCFA Patient’s value, mmol/g protein Reference value, mmol/g protein
C22:0 3.24 2.46–6.59
C24:0 11.76 6.37–13.87
C26:0 1.28 0.16–0.41
Ratio C24:0/C22:0 3.63 1.68–2.92
Ratio C26:0/C22:0 0.4 0.03–0.1
Peroxisomal beta-oxidation Patient’s value, pmol/h ·mg protein Reference values, pmol/h ·mg protein
Activity with C16:0 as substrate 4507 3330–7790
Activity with pristanic acid as substrate 851 790–1690
Peroxisomal beta-oxidation Patient’s C16:0/C22:0 ratio Reference C16:0/C22:0 ratio
Activity with C22:0 shown by a C16:0/C22:0 ratio 0.22 0.42–1.71
VLCFA= very long chain fatty acid.
Bold values in table are elevated values exceeding the reference confirming the diagnosis of X-ALD.
Płatek et al. Medicine (2018) 97:49 www.md-journal.com
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peroxisomes. We sequenced genes known from earlier studies on
congenital BA synthesis deficiencies or catalyzing key steps in
synthesis of CA and CDCA.
Gan-Schreier et al suggested that transport of the VLCFA and
BAs is mediated by a common translocator—ALDP, for which
they compete. It has been demonstrated in studies on mouse and
rat peroxisomes that incubation at high concentrations of
VLCFAs inhibited the conjugation of BAs with taurine.[16] These
studies suggest that BAs and VLCFAs transport can be activated
by the same enzymes or transported into peroxisomes with the
same protein and may compete with each other.
ALDP and PMP70 form homo-oligomers in peroxisomal
membranes; however, in vivo experiments showed their capacity
to form ALDP-PMP70 heterodimers.[17] Braiterman et al[18]
demonstrated that overexpression of PMP70 corrects the VLCFA
b-oxidation defect in skin fibroblasts fromX-ALD patients. It has
been suggested that PMP70 partially constitutes the function of
ALDP, which may explain the residual 10% to 30% VLCFA
b-oxidation activity observed in fibroblasts fromX-ALD patients
and in our patient at the level of 28%.[17,18] Decreased synthesis
of BAs presented in our results could confirm the hypothesis that
PMP70 partially takes over the function of the ALDP protein.
Decreased concentrations of BAs were found only in family
members with the c.659T>C, p.(Leu220Pro) mutation, which
may suggest that it is associated with a mutation in the ABCD1
gene.
In 2 articles published in 2016[19,20] it was demonstrated that
metabolites of cholesterol conversion may play a significant role
in the pathology of X-ALD. Cholesterol biosynthesis occurs
partly in peroxisomes, transformation starts from acetyl-CoA
(presumably derived from peroxisomal VLCFA beta-oxidation)
to farnesyl diphosphate in these organelles with engagement of
Figure 2. Plasma bile acids and sterol profiles in blood plasma in the family members.
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8 enzymes.[21] Nury et al[19] showed that plasma 7-ketocholes-
terol (7KC), a lipid peroxidation product, is increased in X-ALD
patients. 7KC was shown to be formed during oxidative stress
through nonenzymatic chemical oxidation of cholesterol and
induced 3 main symptoms of ALD: inflammation, cell death, and
peroxisomal dysfunction. In another experiment in induced
pluripotent stem cells, derived from fibroblasts of patients with
childhood cerebral ALD, upregulation of cholesterol 25-
hydroxylase (CH25H) with a high production of 25-hydrox-
ycholesterol (25-HC) and subsequent activation of the NLRP3
inflammasome leading to cerebral inflammation were found.[20]
The results of previous studies show accumulation of cholesterol
in the lysosomes from patient fibroblasts with peroxisomal
disorders and from mouse models with silenced ABCD1,
ACOT8, BAAT, TMEM135, PEX1, PEX3, PEX6, PEX10,
PEX26, and NPC1 genes.[22] Furthermore it has been proven
that cholesterol can be transported to peroxisomes from
lysosomes through lysosome-peroxisome membrane contact
with the binding of peroxisomal lipid phosphatidylinositol-4,5-
bisphosphate [PI (4,5)P2] by the lysosomal protein synaptotag-
min VII (Syt7) and requires functionally active of lysosomes and
peroxisomes.[22]
In our study we showed decreased expression of PLEKHA6
and increased LAPTM5 in fibroblasts of X-ALD patients.
PLEKHA6 is expressed in many tissues, with the highest level
in the adult brain, heart, and kidney.[23] It is involved in
intracellular signaling and phosphatidylinositol lipid binding.[24]
There are no published results showing which phospholipids may
be bound to the PLEKHA6 protein. Based on the sequence
similarities between PEPP1 and its homologs, PEPP2 and
PLEKHA6 binding with phosphatidylinositol-3-phosphate was
suggested.[25] PLEKHA6 contains a PH domain, which can
bind phospholipids—phosphatidylinositol-3,4,5-trisphosphate
and PI (4,5)P2.[25] The observed significantly reduced expression
of the PLEKHA6 gene may relate this protein to the pathology of
X-ALD. One of the possible mechanisms is that insufficient
Table 3
Genotypes of family members in the genes related to the synthesis of bile acids and ABC transporters.
Family member
Gene Variant
X-ALD
patient Mother Brother
Gene
region Variant significance/reference
Sequence reference number
(ENSEMBL database)
ABCD1 c.659T>C, p.(Leu220Pro) H HT WT Exon 1 Mutation disease causing/HGMD ID
CM950042. SIFT-deleterious,
PolyPhen- probably damaging.
Human Splicing Finder-potential alternation
on splicing, an exonic ESE site broken.
Mutation taster- splice site changes, donor
increased.
ENST00000218104.5
ABCD3 c.162G>A, p.(=) HM NA NA Exon 3 SNP/rs16946 ENST00000370214.8
CYP7A1 c.-533T>C HM HT HM 5’UTR SNP/rs3824260 ENST00000301645.3
c.-267C>A HM HT HM Promoter SNP/rs3808607
TF binding site
ENST00000301645.3
CYP27A1 c.-357dupC HM HM HM Promoter Variant of unknown significance/
rs397795841
ENST00000258415.8
CYP7B1 No changes were detected
in the sequence
WT NA NA ENST00000310193.3
HSD3B7 c.748A>G, p.(Thr250Ala) HM HM HM Exon 7 SNP/ rs9938550
SIFT-tolerated, PolyPhen-benign.
Human Splicing Finder-potential alternation
on splicing- alternation of an exonic ESE
site and activation of an exonic cryptic
acceptor site, with presence of one or
more cryptic branch point(s). Mutation
taster: splice site changes, donor gained.
ENST00000297679.9
c.1068T>C, p.(=) HM NA NA Exon 7 SNP/rs2305880
AKR1D1 c.-71G>C HT WT NA 5’UTR Unknown effect on the function of the protein ENST00000242375.7
SLC27A5 c.1668-6T>C HM NA NA Intron 8 SNP/ rs4801274
Splice region variant.
Human splicing finder- no significant
splicing motif alternation detected.
ENST00000263093.6
HGMD=The Human Gene Mutation Database, SIFT=Sorting Intolerant from Tolerant, X-ALD=X-linked adrenoleukodystrophy.
Table 4
Gene expression results in adrenomyeloneuropathy and control fibroblasts.
Gene symbol logFC P adj.P FC
PLEKHA6 2.14306539183238 1.12889774338543e-06 .045 4.5
LXN 2.51772157126097 1.56180655690251e-06 .045 5.7
LAPTM5 2.34584037441412 3.19361191947553e-06 .062 5.1
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expression of PLEKHA6 may enhance the problem with
cholesterol transport between lysosomes and peroxisomes in
X-ALD patients. Taking into account the process of cholesterol
transport between lysosomes and peroxisomes with the partici-
pation of phospholipid PI (4,5)P2 anchored in the peroxisome
membrane it is possible that the PLEKHA6 gene may be engaged
in this process probably by the transport or binding of this PI
(4,5)P2 lipid or other phosphoinositides. However, confirmation
of this hypothesis requires further studies.
To summarize in our X-ALD family with AMN we showed a
new disturbance with abnormal C24-BAs (CDCA and CA) levels,
which are the final metabolites of cholesterol conversion
suggesting an additional phenotype related to cholesterol
metabolism. In the studied family no cause of the disorder in
the synthesis of BAs was found. Exome sequencing is required to
find the gene responsible for this disorder, which would allow to
confirm or rule out the hypothesis that the disorder is associated
with the presence of the ABCD1 gene mutation leading to
abnormal function of peroxisomes.
In conclusion, the presented results may be further evidence
that disturbed cholesterol metabolism is important in the
pathology of ALD.
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Methodology: Teresa Płatek, Evelyn Orso, Barbara Zapała,
Anna Polus, Monika Chojnacka.
Project administration: Teresa Płatek.
Resources: Teresa Płatek.
Software: Monika Piwowar.
Validation: Teresa Płatek, Monika Piwowar, Gerd Schmitz.
Visualization: Teresa Płatek, Monika Piwowar, Evelyn Orso.
Writing – original draft: Teresa Płatek.
Writing – review and editing: Evelyn Orso, Barbara Zapała,
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